8-K 1 d316342d8k.htm FORM 8-K Form 8-K

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8 – K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report: March 14, 2012

(Date of earliest event reported)

 

 

MEDICAL ACTION INDUSTRIES INC.

(Exact name of registrant as specified in its charter)

 

 

 

(Former name or former address, if changed since last report)

 

 

 

Delaware   0-13251   11-2421849

(State or other jurisdiction

of incorporation

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

500 Expressway Drive South,

Brentwood, New York

  11717
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number including area code   (631) 231-4600

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 14, 2012, Charles L. Kelly, Jr. resigned as the Chief Financial Officer and Corporate Secretary of Medical Action Industries Inc. (the “Company”), with such resignation to be effective as of March 30, 2012. From March 19, 2012 through March 31, 2012 Mr. Kelly will serve as the Company’s Financial Oversight Specialist, a non executive role. However, Mr. Kelly has agreed to assist with the transition of the Company’s new Principal Financial Officer from March 19, 2012 through March 30, 2012. The Company believes Mr. Kelly’s institutional knowledge is important for the new Principal Financial Officer so upon request Mr. Kelly agreed to stay with the Company for the aforementioned period.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

MEDICAL ACTION INDUSTRIES INC.
By:  

/s/ Paul D. Meringolo

  Paul D. Meringolo
  President & Chief Executive Officer

Dated: March 14, 2012